Asian Currencies Steady as Rupee Hits Record Low Amid Fed Rate Cut Bets 
Germany’s Economic Recovery Slows as Trade Tensions and Rising Costs Weigh on Growth 
European Stocks Rise as Markets Await Key U.S. Inflation Data 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
IKEA Expands U.S. Manufacturing Amid Rising Tariffs and Supply Chain Strategy Shift 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
RBI Cuts Repo Rate to 5.25% as Inflation Cools and Growth Outlook Strengthens 
Dollar Weakens Ahead of Expected Federal Reserve Rate Cut 
Australia’s Economic Growth Slows in Q3 Despite Strong Investment Activity 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
European Oil & Gas Stocks Face 2026 With Cautious Outlook Amid Valuation Pressure 
Spain’s Industrial Output Records Steady Growth in October Amid Revised September Figures 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
South Korea’s JW Pharmaceutical has received a patent in Russia for a hair loss treatment currently under development, marking the first time that its candidate drug has been patented overseas.
The pharmaceutical firm received a patent for JW0061, its Wnt-targeted hair loss treatment, from Russia's Federal Service for Intellectual Property.
The patent covers a new heterocyclic inducer of the Wnt signaling pathway, including its base or isomer, and compositions containing it as an active ingredient.
JW has also submitted patent applications in more than ten nations, including the US, EU, Japan, and China.
JW0061 exhibits a novel method of action by directly binding to the GFRA1 protein in human hair dermal papilla cells, activating the Wnt signaling pathway. This is the first instance of a low-molecular-weight medication that describes the mechanism of hair growth that has been documented.
JW is now evaluating non-clinical toxicity in accordance with good laboratory practice with the intention of initiating clinical trials for JW0061 in the first half of 2024. Additionally, it collaborates on research projects with eminent dermatologists in the US.
JW plans to develop JW0061 as a new innovative drug that supplements or replaces existing hair loss treatments.
